Protalix is a publicly traded, clinical stage biopharmaceutical company (NYSE, TASE: PLX) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx™ plant cell culture protein expression system. ProCellEx provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action.

Protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of Gaucher´s Disease. Protalix has concluded phase III studies for this drug and is currently undergoing FDA review. Treatment is currently being provided by Protalix to Gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. This product has been licensed to Pfizer.

Protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase (Fabry disease) and an anti‐TNF fusion protein (Rheumatoid Arthritis). In addition, Protalix is currently developing a novel technology for the oral-delivery of therapeutic proteins that takes advantage of the plant cell wall properties. Protalix intends to initiate phase I clinical trials of an oral treatment of Gaucher´s Disease in the near future